← Back to Search

Alkylating agent

Oxaliplatin + Paclitaxel for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Renal: Creatinine normal OR Creatinine clearance at least 60 mL/min
Hepatic: Bilirubin normal, SGOT/SGPT no greater than 2.5 times upper limit of normal
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing the combination of two drugs, oxaliplatin and paclitaxel, to see if it is more effective in treating metastatic or unresectable cancer than either drug alone.

Who is the study for?
This trial is for adults with advanced cancers that can't be removed by surgery or have spread, and standard treatments aren't working. They must not have brain metastases, serious heart conditions, severe infections, or certain blood disorders. Pregnant women and those not using contraception are excluded.Check my eligibility
What is being tested?
The study is testing the combination of two chemotherapy drugs, oxaliplatin and paclitaxel, to see how effective they are in treating patients with metastatic or unresectable cancer. It's a Phase I trial which usually means it's early in testing and looking at safe dosage levels.See study design
What are the potential side effects?
Oxaliplatin may cause nerve damage leading to numbness or tingling sensations. Paclitaxel can result in hair loss, joint pain, muscle pains and an increased risk of infection due to low white blood cell counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney function is normal or nearly normal.
Select...
My liver function tests are within normal limits.
Select...
My cancer is advanced and standard treatments are not effective or available.
Select...
I am 18 years old or older.
Select...
I do not have heart failure, unstable chest pain, or irregular heartbeats.
Select...
I do not have cancer that has spread to my brain.
Select...
I can take care of myself but might not be able to do heavy physical work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
316 Previous Clinical Trials
289,686 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,646 Total Patients Enrolled
Eric H. Kraut, MDStudy ChairOhio State University Comprehensive Cancer Center
3 Previous Clinical Trials

Media Library

Oxaliplatin (Alkylating agent) Clinical Trial Eligibility Overview. Trial Name: NCT00004173 — Phase 1
Solid Tumors Research Study Groups:
Solid Tumors Clinical Trial 2023: Oxaliplatin Highlights & Side Effects. Trial Name: NCT00004173 — Phase 1
Oxaliplatin (Alkylating agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004173 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings remaining for participants in this clinical trial?

"According to clinicaltrials.gov, this trial is not currently seeking participants as the data was last updated on May 14th 2013. Nonetheless, there are 41 other studies actively recruiting patients at this time despite the lack of availability for this particular medical study which debuted on October 1st 1999."

Answered by AI

Has this treatment been approved by the Federal Drug Administration?

"At this time, the safety of this treatment has only been evaluated in a Phase 1 trial and thus is estimated at level 1 given the limited data available."

Answered by AI
~14 spots leftby Mar 2025